Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer
Technology appraisal guidance
Reference number: TA816
Published:
Due to operational challenges the committee meeting for Alpelisib in combination with fulvestrant for treating advanced hormone-receptor positive, HER2-negative, PIK3CA-mutated breast cancer will be moving from 18 January 2021 to the 15 March 2021.